Switching to Faricimab for Wet Macular Degeneration — What the Evidence Shows
As newer injection medications become available, one of the most common decisions in retinal practice is whether to switch a patient who is already stable on an existing treatment. Dr Adrian Hunt’s research examined exactly this — what happens when patients with wet age-related macular degeneration switch from established anti-VEGF agents to faricimab, a newer bispecific antibody targeting both VEGF and Ang-2.
Using Fight Retinal Blindness! registry data, the study found good visual outcomes nine months after switching, providing reassurance that the transition can be made safely in routine clinical practice. The findings were published in Clinical & Experimental Ophthalmology in 2025.
Dr Hunt presented this research as an oral presentation at the American Society of Retina Specialists (ASRS) annual meeting in 2024, where it was covered by Healio Ophthalmology. The published paper was subsequently selected as Editor’s Choice by the American Academy of Ophthalmology and featured in Academy Express for international promotion.
What this means for patients: For patients with wet macular degeneration who are already receiving regular eye injections, this research provides evidence that switching to a newer medication can maintain outcomes — and potentially extend the time between injections.